Free antibodies-to-infliximab are biomarker for predicting the effect of dose intensification in pediatric Crohn’s disease patients with secondary loss of response

BACKGROUND: Immunogenicity to antitumor necrosis factor alpha agents, such as infliximab (IFX), may lead to therapeutic failure. OBJECTIVES: This study evaluated the relationship between free and total antibodies-to-infliximab (ATIs), trough levels (TLs) of IFX, and the response to dose intensificat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Eun Sil, Kwon, Yiyoung, Choe, Yon Ho, Kim, Mi Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164862/
https://www.ncbi.nlm.nih.gov/pubmed/37168401
http://dx.doi.org/10.1177/17562848231170948

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164862/
https://www.ncbi.nlm.nih.gov/pubmed/37168401
http://dx.doi.org/10.1177/17562848231170948

Ejemplares similares